

3.15 Standing Order for supply of Sodium Citrotartrate

TITLE	Standing order for Sodium Citrotartrate (adults only)
Trade Name(s)	Citralite, Citravescent, Ural
Presentation¹	Powder for reconstitution containing 3.7g or 4g sodium citrotartrate
Indication	Symptom management of dysuria in adult patients only
Contraindications¹	<ul style="list-style-type: none"> Renal failure / renal impairment Hypernatraemia / heart failure / hypertension / peripheral or pulmonary oedema / where low sodium intake is indicated Pregnancy Breastfeeding mothers
Precautions¹	Nil specific
Dose¹	1 – 2 reconstituted sachets (3.7 – 8g)
Dose frequency¹	3 – 4 times a day
Administration¹	<p>May be administered in hospital and supplied via pre-labelled stock for use outside the hospital. Patient information sheet must be included)</p> <p>Reconstitute powder as directed by product packaging.</p>
Storage	Must be stored out of patient and public access, preferably in a locked room or a locked cabinet securely attached to the wall or floor – see PD2013_043.
Adverse effects¹	<ul style="list-style-type: none"> Mild laxative effect Prolonged use may cause systematic alkalosis and / or hypernatraemia
Nursing Accreditation Requirements	An RN whose competency to practice Nurse Delegated Emergency Care and to comply with this Standing Order has been assessed and approved by a <i>Local Facilitator</i> , in accordance with the NDEC Education and Accreditation Framework.
Documentation	Administration record is to be documented by the administering nurse. Document on the “once only” section of the appropriate medication chart. The record of administration must be checked and countersigned by a medical officer within 24 hours of initial administration.
Related Documents	NDEC Nurse Management Guideline: Urinary Symptoms http://www.ecinsw.com.au/node/278

Local Standing Order Authorisation:

Date approved by _____ LHD Drugs and Therapeutics Committee:	Medical Officer Name:
Review Date:	Signature:

¹ The drug information provided is to act as a guide only, for further information reference should be made to the full product info available on MIMS or the Australian Medicines Handbook <accessible in NSW Health facilities via CIAP: > If contraindications, precautions or interactions are present refer to MO before administration